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Background: We have previously reported that there is little evidence of population ‘cure’ among two populations of
women diagnosed with invasive breast cancer. ‘Cure’ has not yet been examined in the context of screen-detection.
Patients and methods:We examined cancer registry data on 19 800 women aged 50–70, diagnosed with a primary,
invasive, non-metastatic breast cancer between 1 April 1989 and 31 March 2011 in the West Midlands region of England,
linked to Hospital Episode Statistics (HES) and the National Breast Screening Service (NBSS). Follow-up was complete
on all women up to 31 July 2012. Analyses were stratiﬁed by screening status, age, tumour stage, deprivation and
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ethnicity. We estimated net survival for the whole cohort and each subgroup. Population ‘cure’ was evaluated by ﬁtting
ﬂexible parametric log-cumulative excess hazard regression models in which the excess hazard of breast cancer death
was assumed to be equal to zero after a given follow-up time.
Results: There was an overall lack of evidence for ‘cure’. Across all subgroups examined, the general pattern was that of
a continuous decrease in net survival over time, with no obvious asymptotic tendency within 12 years of follow-up.
Model-based analyses conﬁrmed this observation.
Conclusions: Despite dramatic improvements in survival over past decades, diagnosis with breast cancer remains
associated with a small but persistent increased risk of death for all groups of women, including those whose cancer is
detected asymptomatically. These ﬁndings are unlikely to be due to methodological inadequacies. Communication of
these long-term consequences of breast cancer among women recently diagnosed and to those considering undergoing
screening should take due consideration of these patterns.
Key words: breast cancer, ‘cure’, deprivation, early diagnosis, screen-detection, population-based
introduction
Associated with the substantial and welcome increase in survival
for the majority of cancer patients over the past 40 years [1–3]
has been an increased interest in the statistical estimation of
population ‘cure’ [4, 5]. ‘Cure’ in this context is the point at
which a group of cancer patients is observed to have no excess
mortality (due to their cancer) in comparison with the popula-
tion from which they were drawn (Figure 1). At the point of
‘cure’, the group of cancer patients are no longer more likely to
die than if they had never been diagnosed with cancer.
We previously found little evidence that this point of ‘cure’
was reached after 23 years of follow-up among two populations
of women diagnosed with invasive breast cancer in England and
Australia during the 1980–1995 [6]. Subsequent analyses have
supported this conclusion [7, 8].
‘Cure’ among breast cancer patients has not yet been exam-
ined in the context of screen-detection. It is possible that micro-
metastases, a likely candidate for the continued excess mortality
seen in breast cancer patients overall [9], may be absent in the
subpopulation diagnosed asymptomatically via screening. This
subgroup would not then experience any long-term excess
(cancer-related) mortality. This question is of great interest in
the context of the recent review of the beneﬁts and harms of
mammographic screening [10] and the expansion of the screen-
ing age range in the UK to women aged 49–73 years [11].
Contrasting with survival, population ‘cure’ is independent of
lead-time bias [12]. Indeed, the additional time afforded by
early detection inﬂates cancer survival estimates at a given point
in time after diagnosis, while it does not affect the proportion of
patients who eventually display no long-term excess mortality.
We aim here to establish whether women who are diagnosed
asymptomatically via screening display long-term excess mortal-
ity. We also analyse patterns by socioeconomic status and ethni-
city to investigate whether these impact ‘cure’.
materials andmethods
cohort selection
We examined women aged 50–70, diagnosed with a primary, invasive, non-
metastatic breast cancer between 1 April 1989 and 31 March 2011 in the
West Midlands region of England. Only those who had been continuously
eligible for screening from the age of 50 onwards were included (described
in detail elsewhere [13]). Cancer registry data on these individuals were
obtained from the West Midlands Cancer Intelligence Unit and Breast
Screening Quality Assurance Reference Centre [14]. Additional information
was provided by Hospital Episode Statistics (HES) records individually
linked to National Breast Screening Service (NBSS) data. Follow-up was
complete on all women up to 31 July 2012.
tumour stage
Information on tumour size, nodal involvement and presence of metastases
was used to establish each woman’s extent of disease at diagnosis, either
localised (conﬁned to the organ of origin) or regional (spread to adjacent
muscle, organ, fat, connective tissue or regional lymph nodes). Those with
distant metastases were excluded from all analyses a priori, since ‘cure’ was
not a reasonable expectation for these women.
deprivation
Deprivation was measured using the income domain of the English indices of
deprivation for 2004, 2007 or 2010 [15–17]. These scores are derived from
routine administrative data, pertaining to the years 2001, 2005 and 2008,
respectively, for each of the 32 482 Lower Super Output Areas as deﬁned at the
2001 census (LSOAs, ∼1500 people). The scores are categorised according to
the quintiles of their national distribution. Each woman was assigned to one of
ﬁve deprivation levels on the basis of her address of residence when diagnosed.
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Figure 1. ‘Cure’ in a hypothetical group of cancer patients.
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Our approach for deriving ethnicity information for this cohort has been
described [13]. Brieﬂy, data on each woman’s ethnicity were gathered from
self-reports given on admittance to hospital (from HES data, 83% of
women), or where this was missing, on presentation for breast screening
(from NBSS data, 7%). We imputed the remaining 10% of ethnicity data
using name recognition software, Onomap [18]. This software matches the
ﬁrst and last names of the cohort patients with databases of names from
different ethnicities.
estimation of net survival and ‘cure’
We estimated net survival using the non-parametric Pohar Perme estimator
[19] implemented in stns: software available for Stata 13. Net survival pro-
vides an estimate of survival from the cancer itself, adjusting for expected
mortality from other causes, which was obtained from ethnic-speciﬁc life
tables for England and Wales adjusted for deprivation [20].
We ﬁtted ﬂexible parametric log-cumulative excess hazard regression
models [21] to estimate the age-adjusted excess hazard of breast cancer
death. Models were ﬁtted to follow-up times up to the 95th centile of (all)
deaths. We assessed the linearity and time-dependence of age at diagnosis by
the inclusion of restricted cubic splines, with the knots placed within the
range of the data. Population ‘cure’ was then evaluated from the most parsi-
monious age-adjusted model by assuming that the excess hazard became
equal to zero from a given time (as implemented in the software stpm2) [22,
23]. The ﬁnal model was selected based on the lowest Akaike’s information
criterion (AIC) with a reduction of 3 or more in the AIC between successive
models [24]. Where the difference between the ‘cure’ model and the age-
adjusted model showed a reduction of 3 or more in the AIC, there was taken
to be evidence of ‘cure’. The presence of ‘cure’ was also assessed by visual
inspection of the survival curves.
co-variables examined
Analyses were stratiﬁed by screening status (screen-detected/not-screen-
detected). Additionally, we examined ‘cure’ by age (50–59/60–70 years),
tumour stage (localised/regional), deprivation quintile [less deprived (quin-
tiles 1 and 2)/more deprived (quintiles 3–5)] and ethnicity (White/Asian/
Black). We also conducted a restricted analysis of localised cases only, by
both age and deprivation.
results
The analysis included 19 800 women who had a ﬁrst primary
malignant breast tumour which was not classiﬁed as distant at
diagnosis (mean age 57.5 years, standard deviation = 5.0).
There was an overwhelming lack of evidence for ‘cure’.
Despite high survival at 1, 5 and 10 years across the subgroups
examined (deﬁned by screening status, tumour stage, age,
deprivation and ethnicity), there was a general pattern of a
continuous decrease in net survival through time, with no
obvious asymptotic tendency within 12 years (Figure 2, supple-
mentary Figures S1–S3, available at Annals of Oncology online).
The model-based analyses conﬁrmed this observation; no ‘cure’
models were found to ﬁt well for any subgroup examined
(Table 1, supplementary Tables S1–S3, available at Annals of
Oncology online).
Models did not always converge. Among the screen-detected
group, parametric survival models could not be ﬁtted for either
Black or Asian women due to small numbers of patients and
deaths in these groups. Fitting an asymptote to the age-adjusted
model for women with regional disease also proved
unachievable. For these women, ‘cure’ was not assessed using
the modelling approach.
The one subgroup which displayed a different pattern was af-
ﬂuent women screen-detected with localised disease (Figure 3).
Here, survival was very high, in excess of 98% after 10 years.
The net survival curve tended slightly towards an asymptote,
and the model also conﬁrmed a ﬂattening of the curve. The
‘cure’ model did not, however, display a better ﬁt than the age-
adjusted model alone.
discussion
We have shown that there is a persistent lack of ‘cure’ among
this cohort of middle-aged women diagnosed with breast cancer
for all sociodemographic groups, even if their cancer is localised
and/or detected via screening. Elevated mortality for all groups
persists beyond the 10th anniversary of diagnosis.
There was suggestive, but weak, evidence of ‘cure’ around 12
years after diagnosis for less deprived women with localised
disease whose cancer was detected via screening. Although the
net survival curve tended to level from the 11th year following
diagnosis, the model-based analysis did not support the hypoth-
esis that ‘cure’ was present, however.
strengths and limitations
Our approach has several strengths in comparison with previous
studies. Life tables speciﬁc, not just to the deprivation proﬁle of
this population, but also its ethnic mix, were applied to obtain
the most accurate estimates of expected mortality in this setting.
Screening status was established on the basis of individually
linked data, and we restricted the cohort to women whom we
know to have been invited for screening from their 50th birth-
day onwards. The inﬂuence of screen-detection upon ‘cure’ is
not thus obscured by older women attending screening for the
ﬁrst time at ages over 50 years. We used ﬂexible models to test
the existence of ‘cure’, rather than one which assumes its exist-
ence, as necessitated by other methods [5, 7]. This means that
the presence of the ‘cured’ proportion can therefore be formally
evaluated. As the AIC assesses the whole curve, however, while
for ‘cure’ the tail of the curve (where there are more sparse data)
is most important, caution must be exercised in relying solely on
this evaluation. To this end, the need for visual inspection of the
net survival curves continues to be emphasised [7], which we
did, with the same conclusions.
There are limitations of our analysis. Breast cancer survival is
high, thus there were a relatively small number of deaths in our
data. We therefore restricted all analyses to the ﬁrst 95% of deaths
to reduce poor model ﬁt in particular at the end of follow-up.
A related concern is the inappropriateness of the AIC for evalu-
ating ‘cure’ models [7], because the AIC is less sensitive to the
portion of follow-up where ‘cure’ occurs. However, deaths here oc-
curred at a steadily decreasing rate throughout follow-up, with a
not-so-skewed distribution of times to death (mean time to death
4.34 years, median 3.24 years, inter-quartile range 1.55–6.06).
We have previously evaluated cure up to 23 years after diag-
nosis. Although the maximum follow-up of the present cohort
was similar, our cautious restriction of examining ‘cure’ only up
to the 95th centile deaths meant that the effective follow-up was
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Figure 2. Non-parametric and modelled estimates of net survival up to 12 years following diagnosis. (A) All women. (B) All women, localised disease. (C) Screen-detected women. (D) Screen-detected women,
localised disease. (E) Non-screen-detected women. (F) Non-screen-detected women, localised disease. (G) Women aged 50–59 years at diagnosis. (H) Women aged 60–70 years at diagnosis. (I) Less deprived
women (quintiles 1 and 2). (J) More deprived women (quintiles 3–5). (K) Asian women. (L) Black women.
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Table 1. Evidence of ‘cure’ by screen-detection status: women diagnosed in the West Midlands region of England 1989–2011
All Screen-detected women Non-screen-detected women
n (%) Deaths (% of n) Evidence of ‘cure’?a n (%) Deaths (% of n) Evidence of ‘cure’? n (%) Deaths (% of n) Evidence of ‘cure’?
All women 19 800 (100.0) 3153 (15.9) No evidence 10 466 (100.0) 984 (9.4) No evidence 9334 (100.0) 2169 (23.2) No evidence
Age at diagnosis
50–59 years 12 933 (65.3) 2316 (17.9) No evidence 6563 (62.7) 699 (10.7) No evidence 6370 (68.2) 1617 (25.4) No evidence
60–69 years 6867 (34.7) 837 (12.2) No evidence 3903 (37.3) 285 (7.3) No evidence 2964 (31.8) 552 (18.6) No evidence
Extent of disease at diagnosisb
Localised 12 176 (61.5) 1121 (9.2) No evidence 7548 (72.1) 499 (6.6) No evidence 4628 (49.6) 622 (13.4) No evidence
Regional 6364 (32.1) 1721 (27.0) No convergence 2385 (22.8) 422 (17.7) No evidence 3979 (42.6) 1299 (32.6) No evidence
Ethnicityc
White 19 040 (96.2) 3030 (15.9) No evidence 10 087 (96.4) 949 (9.4) No evidence 8953 (95.9) 2081 (23.2) No evidence
Asian 572 (2.9) 85 (14.9) No evidence 293 (2.8) 25 (8.5) No convergence 279 (3.0) 60 (21.5) No evidence
Black 188 (0.9) 38 (20.2) No evidence 86 (0.8) 10 (11.6) No convergence 102 (1.1) 28 (27.5) No evidence
Deprivation quintiled
Less deprived (1 and 2) 8592 (43.4) 1186 (13.8) No evidence 4519 (43.2) 345 (7.6) No evidence 4073 (43.6) 841 (20.6) No evidence
More deprived (3–5) 11 190 (56.5) 1964 (17.6) No evidence 5940 (56.8) 639 (10.8) No evidence 5250 (56.2) 1325 (25.2) No evidence
Among localised cases only n = 12 176 (100.0) n = 7548 (100.0) n = 4628 (100.0)
Age at diagnosis
50–59 years 7701 (63.2) 796 (10.3) No evidence 4576 (60.6) 335 (7.3) No evidence 3125 (67.5) 461 (14.8) No evidence
60–69 years 4475 (36.8) 325 (7.3) No evidence 2972 (39.4) 164 (5.5) No evidence 1503 (32.5) 161 (10.7) No evidence
Deprivation quintile
Less deprived (1 and 2) 5379 (44.2) 410 (7.6) No evidence 3276 (43.4) 159 (4.9) No evidence 2103 (45.4) 251 (11.9) No evidence
More deprived (3–5) 6791 (55.8) 711 (10.5) No evidence 4267 (56.5) 340 (8.0) No evidence 2524 (54.5) 371 (14.7) No evidence
aAs determined by the difference in the AIC: reduction of 3 or more = evidence of ‘cure’; increase or a reduction of <3 = no evidence of ‘cure’; ‘cure’model unable to converge = ‘no convergence’.
bUnstaged cancers (n = 1260) were excluded from extent-specific analyses.
cIndividual ethnicity: White includes all categories other than Asian and Black (see text).
dQuintile of the IMD income domain score of the woman’s LSOA of residence at diagnosis (see text). Women with missing data were excluded (n = 18).
Volum
e
27
|N
o.11
|N
ovem
ber2016
doi:10.1093/annonc/m
dw
408
|

A
nnals
ofO
ncology
originalarticles
much shorter: 12.3 years. It is possible that ‘cure’ could be
reached by survivors remaining after this time, although the tra-
jectory of the survival curves suggests that this is very unlikely.
We excluded conﬁrmed distant (metastatic) cancers from our
analyses since we did not reasonably expect ‘cure’ to be attained
for these patients. However, because we also included unstaged
tumours in the overall analyses, survival reported here for all
patients is a slight underestimate of the survival of women with
localised or regional tumours.
possible causal explanations
Persistent excess mortality due to cancer among screen-detected
women into the second decade following their diagnosis seems
unlikely to be due to treatment inadequacies at the time of the
initial diagnosis, but rather more likely to be due to long-term
effects of either the cancer itself or of its treatment, and, or the dis-
tinctive natural history of this malignancy. For example, some
women whose disease is apparently localised at diagnosis harbour
micro-metastatic disease: it is possible that this is also the case
among women who are asymptomatic and screen-detected.
The data available did not allow us to investigate ‘cure’ by mo-
lecular subtype of breast cancer (e.g. luminal A or B, triple nega-
tive, HER2). Certain subtypes may have already metastasised
even when the tumour itself is localised [25, 26], which could
partly explain the lack of cure in the cohort overall.
A further hypothesis has been proposed that the act of breast
cancer surgery itself provokes the activation of latent micro-me-
tastases [27, 28]. However, this mechanism has been suggested
only among pre-menopausal women, whereas women under 50
were not included in this study.
public health considerations
The public health implications of these ﬁndings are twofold.
First, our analysis strongly suggests that despite very high sur-
vival overall, women diagnosed with breast cancer experience a
continuing risk of death from cancer beyond the 10th anniver-
sary of their diagnosis, and that this occurs irrespective of their
extent of disease at diagnosis. This has implications for the way
in which clinicians, policy makers and public health profes-
sionals communicate with patients regarding the long-term
prognosis to women newly diagnosed with breast cancer. In par-
ticular, data such as these question whether a woman diagnosed
once with breast cancer can be considered to be disease-free,
and increases the importance of using the correct language
when communicating with those who have previously been
treated for breast cancer [29, 30]. Second, since the pattern is
consistent for both screen-detected and non-screen-detected
women, our data suggest that screening does not afford protec-
tion from long-term excess mortality, even though it is asso-
ciated with an important and signiﬁcant survival advantage at
all times since diagnosis, independent of lead-time bias [13].
Communication of this important and unique feature of breast
cancer to those women considering screening and diagnosed via
screening should also be carefully considered.
conclusion
Our analyses have shown an overwhelming lack of evidence for
‘cure’ in our cohort of breast cancer patients. We have demon-
strated continued excess mortality up to 12 years after diagnosis,
irrespective of age, screening status, stage of disease, ethnicity or
deprivation status. These ﬁndings are unlikely to be due to
methodological inadequacies. Despite high and continually
increasing survival among middle-aged women diagnosed in
the UK, breast cancer leads to a tiny, but persistent, increased
risk of death for all groups of women, including those whose
cancer is detected asymptomatically. Communication of the
long-term consequences of breast cancer among women recent-
ly diagnosed and to those considering undergoing screening
should take due consideration of these patterns.
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